TCGA-18-3410-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.430
- MYC_TARGETS_V1+0.380
- ALLOGRAFT_REJECTION+0.340
- DNA_REPAIR+0.310
- MYC_TARGETS_V2+0.240
- INTERFERON_GAMMA_RESPONSE+0.230
- PI3K_AKT_MTOR_SIGNALING+0.210
- IL6_JAK_STAT3_SIGNALING+0.200
- OXIDATIVE_PHOSPHORYLATION+0.180
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.400
- COAGULATION-0.390
- HEDGEHOG_SIGNALING-0.390
- MYOGENESIS-0.360
- ANGIOGENESIS-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- UV_RESPONSE_DN-0.310
- ESTROGEN_RESPONSE_EARLY-0.300
- NOTCH_SIGNALING-0.280
- GLYCOLYSIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6433-01A-11R-1686-07 | — | — | 0.852 |
| 2 | SRR8518289 | — | E | 0.850 |
| 3 | SRR12202418 | — | — | 0.829 |
| 4 | 6649e671-1660-4d4d-8f1e-bb697486b439 | — | — | 0.828 |
| 5 | MBCProject_1542_T2_RNA | — | D | 0.827 |
| 6 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.809 |
| 7 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.809 |
| 8 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.806 |
| 9 | TCGA-DK-A1A6-01A-11R-A13Y-07 | — | — | 0.805 |
| 10 | SRR1313144 | — | D | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |